Oral CBD Did Not Significantly Reduce Seborrheic Dermatitis in Parkinson's Patients in Small Trial

CBD treatment did not significantly reduce seborrheic dermatitis severity or presence. However, the CBD group showed a non-significant trend toward improvement (risk ratio 0.69 for post vs pre) while the placebo group showed a non-significant trend toward worsening (risk ratio 1.20). The between-group difference approached significance (p = .07).

Randomized (1:1), parallel, double-blind, placebo-controlled trial. 53 Parkinson's patients (27 placebo, 26 CBD) received 16 days of oral CBD-rich cannabis extract (2.5 mg/kg/day CBD with 0.08 mg/kg/day THC) or placebo. Facial photographs were scored independently using the SEDASI scale by blinded reviewers.

Seborrheic dermatitis affects up to 59% of people with Parkinson's disease and is difficult to treat. While this trial was too small and short to detect a clear effect, the opposing trends between CBD and placebo groups suggest CBD may have dermatological effects worth investigating in larger studies.

CBD has demonstrated anti-inflammatory and sebum-regulating properties in preclinical studies. This trial was designed primarily to test CBD's effects on Parkinson's motor symptoms, with seborrheic dermatitis as a secondary outcome, explaining why it was underpowered for this skin condition.

Substantially underpowered for the dermatological outcome. Treatment duration of only 16 days may be insufficient for skin conditions. Baseline seborrheic dermatitis severity was low in both groups, creating a floor effect. The oral route may not deliver adequate concentrations to skin.